Open access
7,840
Views
6
CrossRef citations to date
0
Altmetric
Review
High concentration formulation developability approaches and considerations
Jonathan Zarzara Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USACorrespondence[email protected]
View further author information
, View further author information
Tarik Khanb Pharma Technical Development Europe, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Maniraj Bhagawatic Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, GermanyView further author information
, Benjamin Weichec Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, GermanyView further author information
, Jasmin Sydow-Andersenc Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, GermanyView further author information
& Alavattam Sreedharaa Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USAView further author information
Article: 2211185
|
Received 27 Jan 2023, Accepted 02 May 2023, Published online: 16 May 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.